J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Investors punish the liquid biopsy maker for lacklustre data on its colorectal cancer screen.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.